Results 41 to 50 of about 518,020 (377)
Experimental measurement and numerical modelling of dye washout for investigation of blood residence time in ventricular assist devices [PDF]
, 2018 Ventricular assist devices have become the standard therapy for end-stage heart failure. However, their use is still associated with severe adverse events related to the damage done to the blood by fluid dynamic stresses.
Fraser, Katharine +5 more
core +2 more sources
Clinical and Applied Thrombosis/Hemostasis, 2021 Measurement of a single marker of coagulation may not provide a complete picture of hemostasis activation and fibrinolysis in patients with chronic cardiovascular diseases. We assessed retrospective orders of a panel which included prothrombin fragment 1.
Maureen J. Miller MD, MPH +3 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 BackgroundRepeat hospitalizations, complications, and psychosocial burdens are common in patients with left ventricular assist devices (LVAD). Specialist palliative care (sPC) involvement supports patients during decision-making until end-of-life. In the
Theresa Tenge +18 more
doaj +1 more source
Heart Rate Variability: A possible machine learning biomarker for mechanical circulatory device complications and heart recovery [PDF]
, 2020 Cardiovascular disease continues to be the number one cause of death in the United States, with heart failure patients expected to increase to \u3e8 million by 2030.
Aras, Shravan +2 more
core +1 more source
Restoration of myocardial β-adrenergic receptor signaling after left ventricular assist device support [PDF]
, 2006 ObjectiveLeft ventricular assist device support for patients with chronic heart failure can significantly improve β-adrenergic receptor signaling, which is likely critical to myocardial recovery.
Akhter, Shahab A. +3 more
core +1 more source
Heart Failure Anticoagulation Teach-Back Education and Readmissions [PDF]
, 2020 : Heart failure affects millions of Americans each year. Treatment of advanced heart failure with reduced ejection fraction and left ventricular failure is sometimes treated with implantation of a left-ventricular assist device.
core
Percutaneous Ventricular Assist Devices: New Deus Ex Machina? [PDF]
, 2011 The development of ventricular assist devices has broadened the means with which one can treat acute heart failure. Percutaneous ventricular assist devices (pVAD) have risen from recent technological advances.
Arroyo, Diego, Cook, Stéphane
core +3 more sources
Reviews in Cardiovascular Medicine, 2022 Echocardiography (ECHO) is indispensable for evaluation of patients with terminal chronic heart failure (HF) who require transplantation or mechanical circulatory support by a left- or biventricular assist device (LVAD or BiVAD, respectively).
Michael Dandel
doaj +1 more source
Mechanical circulatory support for destination therapy. [PDF]
, 2016 Patients with chronic heart failure who are not eligible for heart transplant and whose life expectancy depends mainly on the heart disease may benefit from mechanical circulatory support.
Hullin, R., Tozzi, P.
core +1 more source
Ethical challenges with the left ventricular assist device as a destination therapy
Philosophy, Ethics, and Humanities in Medicine, 2008 The left ventricular assist device was originally designed to be surgically implanted as a bridge to transplantation for patients with chronic end-stage heart failure.
Rady Mohamed Y +3 more
doaj +1 more source